Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
Jairia Dela Cruz, 05 Jan 2017
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.

Excerpts from the expert meeting on the use of topical NSAIDs in musculoskeletal pain

01 Jul 2018
With the objective of establishing a Malaysian consensus on the use of topical NSAIDs in the management of musculoskeletal pain, this meeting brought together experts from various backgrounds, ie, rheumatology, pharmacy, orthopaedics and general medicine. At the meeting, Dr Mary Suma Cardosa delivered a talk on the pathophysiology and effective management of pain, while the lecture by Dr Yeap Swan Sim focused on the management of musculoskeletal and soft-tissue pain. This article presents excerpts from the expert meeting and features the consensus statements agreed during the meeting.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
Jairia Dela Cruz, 05 Jan 2017
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.